Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on endovascular robotics through its LIBERTY Endovascular Robotic System. The news around MBOT centers on the commercialization of this FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and the company’s progress in bringing it into routine clinical use.
Investors and clinicians following Microbot Medical can find updates on key commercial milestones, such as the limited market release of LIBERTY in selected high procedure volume regions in the U.S. and the company’s plans for a broader market release aligned with major medical conferences. News items also cover the first hospital adoption of LIBERTY for patient care at Emory University Hospital and the collaboration to build an Endovascular Robotics Program in interventional radiology.
Coverage of MBOT includes regulatory and clinical developments, including FDA 510(k) clearance for LIBERTY and reported data from the ACCESS PVI pivotal trial, where the company cites 100% robotic navigation success, a 92% reduction in radiation exposure and no adverse device events. Additional articles highlight Microbot Medical’s presence at professional meetings, its partnerships with third-party manufacturers and logistics providers, and its work on teleintervention and autonomous robotics collaborations.
Financial and corporate news for Microbot Medical features capital-raising activities through exercises of preferred investment options, as well as updates on its intellectual property portfolio, such as new patents in jurisdictions including Japan. For readers tracking MBOT, this news feed offers a focused view of how the company is advancing the LIBERTY System, expanding its commercial infrastructure and executing on its endovascular robotics strategy over time.
Microbot Medical (NASDAQ: MBOT) highlighted updated occupational protection guidelines from SIR and CIRSE on April 22, 2026, which address radiation exposure, ergonomic risks and pregnancy protections for interventional staff.
The company positioned its LIBERTY Endovascular Robotic System as a potential solution to reduce radiation exposure and musculoskeletal strain, noting endorsements from at least nine medical societies and an AMA policy adopted in late 2025.
Microbot Medical (Nasdaq: MBOT) will present commercial progress supporting the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference.
The live webcast is April 15, 2026 at 10:15 a.m. ET; management will discuss growth strategy, physician radiation mitigation, staffing benefits, and offer one-on-one investor meetings.
Microbot Medical (Nasdaq: MBOT) has commenced the full market release (FMR) in the U.S. of its LIBERTY® Endovascular Robotic System after a successful limited market release (LMR).
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and has been adopted by leading systems including Emory Healthcare and Tampa General Hospital. The system has been used commercially for PAE, UFE, GAE, Y90 mapping and deliveries, and peripheral arterial interventions. Commercial footprint expanded from 4 to 8 sales territories with a goal of 12 territories by end of 2026.
Microbot Medical (Nasdaq: MBOT) announced that Emory Healthcare completed the first robotic Prostatic Artery Embolization (PAE) and the first robotic Y-90 radioembolization mapping using the LIBERTY® Endovascular Robotic System on March 26, 2026. The single-use, FDA-cleared LIBERTY system aims to improve precision, reduce radiation exposure, and expand access to peripheral endovascular care. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to deepen clinical adoption.
Microbot Medical (NASDAQ: MBOT) announced publication of the ACCESS-PVI pivotal study in the Journal of Vascular and Interventional Radiology on March 24, 2026. The multicenter feasibility study completed in 2025 and underwent independent peer review. The LIBERTY system received FDA clearance in September 2025 and had a limited market release in late 2025, with a planned full market release at the SIR conference in April 2026.
The publication strengthens the clinical evidence base supporting broader commercial adoption of the single-use LIBERTY endovascular robotic system.
Microbot Medical (Nasdaq: MBOT) will present at the 38th Annual Roth Conference March 22-24, 2026, with a live webcast fireside Q&A on March 23, 2026 at 4:00 pm PT. CEO Harel Gadot will discuss LIBERTY commercial progress, limited market release traction, and plans for a full market release in April 2026 at SIR.
The webcast is available via the company’s Investors site and the presentation aims to showcase product differentiation, physician safety benefits, and upcoming commercialization steps.
Microbot Medical (Nasdaq: MBOT) will participate for the first time in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, March 16-19, 2026.
CEO Harel Gadot will present a live webcast on March 19 at 8:40 am ET highlighting LIBERTY® limited market release progress, clinical experience, and growth drivers ahead of a planned full market release at SIR in April 2026.
Microbot Medical (Nasdaq: MBOT) endorsed the American Medical Association’s late-2025 policy expanding protections against occupational ionizing radiation. The company highlights its LIBERTY Endovascular Robotic System as a safety solution: ACCESS-PVI showed a 92% relative reduction in radiation exposure. LIBERTY is FDA-cleared, single-use, remotely operated, entered a Limited Market Release in late 2025, and aims for a Full Market Release at SIR in April 2026.
The system also enables seated operation away from radiation, reducing reliance on heavy PPE and musculoskeletal strain for providers.
Microbot Medical (Nasdaq: MBOT) confirms no business disruption in the U.S. or Israel amid current geopolitical events and says employee safety is the top priority. The company says internal operations and its lead manufacturing partner remain fully functional, with sufficient U.S. inventory to support customers.
Following FDA clearance, Microbot began a limited market release of the LIBERTY Endovascular Robotic System in late 2025 and plans a full market release at the SIR conference in April 2026. The company is expanding U.S. commercial infrastructure with new sales hires and a Director of HEOR, and is building additional U.S. stock via a third-party logistics partner.
Microbot Medical (Nasdaq: MBOT) announced Tampa General Hospital is the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System following the Company's recent FDA 510(k) clearance. The limited market release began in late 2025, with a planned full market release at the Society of Interventional Radiology conference in April 2026.
LIBERTY is described as the only FDA‑cleared, single‑use, remotely operated robotic system for peripheral endovascular procedures, aiming to improve navigation precision and reduce radiation and ergonomic strain.